Distal tubular acidosis induced by FK506

This study was designed to investigate the effect of tacrolimus (FK506) and of cyclosporine (CSA) on tubular function in renal graft recipients. Patients were randomised after renal transplantation to immunosuppressive treatment with FK506 (n = 8) or CSA (n = 8). Patients had a mean age of 45.7 ± 3.4 yr; there was no difference in age, sex, HLA status or CMV mismatches. Neither was there any difference in the frequency of episodes of acute kidney failure between the groups, nor was there a significant difference in the frequency of episodes of kidney rejection within the first year. The mean FK506 level at the time lay at 14.7 ± 14.4 ng/mL whole blood, and the mean CSA level at the time of study was 162± 25 ng/mL whole blood. We performed renal function studies 6 months after transplantation: Cins CPAH NaHCO, loading, and Na 2 SO 4 loading. There was no significant impairment of GFR in patients treated with FK506 with 53.6±2.5 mL/min as compared to 586 mL in group 2. Plasma renin activity (0.6±0.4 ng/mL vs 2.3±3; p <0.01) and aldosterone (69 ±17 vs 157±28.2 pg/mL; p<0.05) were significantly decreased during treatment with FK506. Fractional HCO 3 excretion was low in both groups, indicating that bicarbonate reabsorption in the proximal nephron was unimpaired. Distal renal tubular acidosis was demonstrated in 4 patients of group 1 but in only 1 of group 2. Potassium levels were slightly increased in patients treated with FK506 (5.4±0.2 mmol/L) as compared to cyclosporine (4.9±0.3 mmol/L; p<0.05). Distal hydrogen ion secretion, evaluated by the ability to increase urinary PCO, in a highly alkaline urine, was impaired in patients treated with FK506 (U‐B pCO 2 : 16.1±4 vs 36 ± 5.8; p<0.05) as compared to patients treated with CSA. The maximum acidification capability (NAE) was slightly lowered during therapy with FK506 (67.5±11.8 versus 86.6± 16.5 μmol/min, ns). We conclude that FK506 administration results in a decrease in the rate of hydrogen ion secretion by the collecting tubules. This defect was disclosed by the finding of a subnormal pCO 2 in a highly alkaline urine. These results show that FK506 is able to induce distal tubular acidosis. Distal tubular acidosis is part of FK506 induced nephrotoxicity, the pathogenesis of this type of hyperkalemic metabolic acidosis found in patients treated with FK506 after renal transplantation has to be further elucidated.